Jeito

Jeito company information, Employees & Contact Information

Updated June 2026

Quick answer

Jeito is a Venture Capital and Private Equity Principals company and founded in 2017. It has approximately 40 employees on record. Contact data was last refreshed in June 2026. Find Jeito's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. We empower and support entrepreneurs through our expert, integrated, multi-talented team. Jeito Capital is based in Paris with a presence in Europe and the United States. Follow us to get our latest news & job offers.

Company Details

Employees
40
Founded
2017
Address
2, Rue Pillet Will, Paris,île-De-France 75009,france
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Website
jeito.life
HQ
Paris, Île-de-France
Looking for a particular Jeito employee's phone or email?

Jeito Questions

News

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs - GlobeNewswire

Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs GlobeNewswire

Affinity Asset Advisors/TPG Life Sciences Innovations Joins $213M Series D For Odyssey Therapeutics - citybiz

Affinity Asset Advisors/TPG Life Sciences Innovations Joins $213M Series D For Odyssey Therapeutics citybiz

Jeito Capital promotes Ksenija Pavletic to General Partner - The Manila Times

Jeito Capital promotes Ksenija Pavletic to General Partner The Manila Times

Jeito Capital Strengthens Leadership for Next Chapter of - GlobeNewswire

Jeito Capital Strengthens Leadership for Next Chapter of GlobeNewswire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Business Wire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors Business Wire

Women-Led Jeito Capital Closes on $630 Million Life Sciences Investment Fund - BioSpace

Women-Led Jeito Capital Closes on $630 Million Life Sciences Investment Fund BioSpace

Jeito Capital Closes Its Latest Fund, Jeito I, at $630m - Private Equity Insights

Jeito Capital Closes Its Latest Fund, Jeito I, at $630m Private Equity Insights

Jeito Capital announces significant participation in $187 - GlobeNewswire

Jeito Capital announces significant participation in $187 GlobeNewswire

French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics - EU-Startups

French PE fund Jeito Capital invests in global biopharma growth with Aviceda and XyloCor Therapeutics EU-Startups

Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic - Fierce Biotech

Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic Fierce Biotech

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing - FinancialContent

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing FinancialContent

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders - Business Wire

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders Business Wire

Jeito Capital leads $67.5 million (€64.4 million[1]) Series - GlobeNewswire

Jeito Capital leads $67.5 million (€64.4 million[1]) Series GlobeNewswire

XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease - Business Wire

XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease Business Wire

Jeito Capital Leads a USD 65 million Financing in ReproNovo - GlobeNewswire

Jeito Capital Leads a USD 65 million Financing in ReproNovo GlobeNewswire

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 - GlobeNewswire

Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 GlobeNewswire

EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies - Business Wire

EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies Business Wire

Top Jeito Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant